Neoadjuvant immunotherapy for melanoma

Clinical trials have demonstrated the efficacy of immunotherapy, especially checkpoint blockade inhibitors, in the treatment of patients with metastatic melanoma. More recently, improvements in survival have been reported in patients with high‐risk resectable melanoma when these agents are used in t...

Full description

Saved in:
Bibliographic Details
Published inJournal of surgical oncology Vol. 123; no. 3; pp. 782 - 788
Main Authors Lee, Ann Y., Brady, Mary S.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.03.2021
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
checkpoint blockade
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
high risk
Humans
Immune Checkpoint Inhibitors - administration & dosage
Immunotherapy
Immunotherapy - methods
Melanoma
Melanoma - immunology
Melanoma - therapy
neoadjuvant
Neoadjuvant Therapy
Randomized Controlled Trials as Topic
resectable
resectable
checkpoint blockade
melanoma
neoadjuvant
high risk
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Clinical trials have demonstrated the efficacy of immunotherapy, especially checkpoint blockade inhibitors, in the treatment of patients with metastatic melanoma. More recently, improvements in survival have been reported in patients with high‐risk resectable melanoma when these agents are used in the adjuvant setting. Increasing interest in neoadjuvant immunotherapy for high‐risk resectable melanoma has been fueled by early reports of significant efficacy. We review the rationale and data behind utilizing neoadjuvant immunotherapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.26229